Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reported Japan Plan To Cut Drug Subsidies Expected To Hit Astellas, Takeda Hardest (Japan)

This article was originally published in PharmAsia News

Executive Summary

Major Japanese pharmaceuticals Astellas and Takeda stand to suffer the most from the government's decision to reduce subsidies for prescription drugs. The government reportedly acted in response to medicine sales that are double those of last year. Takeda makes Blopress (candesartan cilexetil) and Astellas' Micardis (hydrochlorothiaze; telmisartin) for treating high blood pressure. Blopress is the country's best-seller in the hypertension and depression segments, and a prime target for the government cuts. Reports say the government plan includes reducing the prices of popular drugs by 15 to 20 percent under new price caps. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC065912

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel